Masimo has won a major patent infringement lawsuit against Apple, with a California jury awarding the medical technology company $634 million in damages. The jury found that Apple’s Apple Watch infringed Masimo’s patent No. 10,433,776, which relates to blood oxygen monitoring technology, a key feature in health tracking devices[1][2][3].
The verdict, delivered in the U.S. District Court for the Ce...
The verdict, delivered in the U.S. District Court for the Central District of California, confirms the validity of Masimo’s patent and holds Apple liable for unauthorized use of the technology. Masimo, known globally for its noninvasive monitoring solutions such as its Masimo SET® pulse oximetry technology used on over 200 million patients annually, views this outcome as a significant victory in protecting its innovations and intellectual property[2][4].
Masimo issued a statement expressing satisfaction with the j...
Masimo issued a statement expressing satisfaction with the jury's decision, emphasizing the importance of safeguarding their technology to continue developing life-saving healthcare solutions. The company reaffirmed its commitment to defending its IP rights and advancing medical technology[4][5].
This ruling is part of an ongoing legal battle between the t...
This ruling is part of an ongoing legal battle between the two companies, with Masimo accusing Apple of copying its patented technology in Apple Watch models up to 2025. The case highlights the crucial role of intellectual property protection in the tech industry, especially for companies investing heavily in research and development. The substantial $634 million award underscores the jury's recognition of Masimo’s contributions and the infringement by Apple[6][7][9].
The case may have further implications for Apple, as legal p...
The case may have further implications for Apple, as legal proceedings related to import bans and additional patent claims continue. Apple has faced challenges defending the patent claims but has not yet indicated its plans for appeal or settlement following this significant verdict[11].
This legal development marks a notable moment in the interse...
This legal development marks a notable moment in the intersection of medical technology and consumer electronics, emphasizing the value and protection of innovation in wearable health devices.
🔄 Updated: 11/15/2025, 9:20:12 PM
A California federal jury has awarded Masimo $634 million after finding Apple infringed its Patent No. 10,433,776, which covers advanced blood oxygen monitoring technology used in the Apple Watch. The verdict specifically upheld Masimo’s apparatus claims (Claims 11–14), confirming that Apple’s implementation of pulse oximetry in its smartwatches violated Masimo’s patented methods for noninvasive patient monitoring. Masimo stated, “This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients.”
🔄 Updated: 11/15/2025, 9:30:12 PM
Consumer and public reaction to Masimo’s $634 million patent infringement award against Apple has been notably mixed, with many lauding the verdict as a crucial defense of innovation and intellectual property rights. Masimo expressed satisfaction, emphasizing the judgment as a “significant win” that underscores their commitment to protecting technology benefiting patients[2][4]. Meanwhile, some Apple supporters and industry observers view the massive damages as a blow to Apple’s reputation but acknowledge it highlights the importance of respecting patented medical technology innovations[3][7].
🔄 Updated: 11/15/2025, 9:40:48 PM
A California federal jury awarded Masimo $634 million after finding Apple infringed on Masimo’s patented blood oxygen monitoring technology, specifically Patent No. 10,433,776, used in Apple Watch features. This patent covers advanced pulse oximetry innovations critical for accurate, noninvasive blood oxygen and patient monitoring, technologies Masimo has refined and deployed on over 200 million patients annually. The verdict underscores the importance of protecting specialized medical sensor innovations as Apple integrates such tech into consumer wearables, potentially impacting future product designs and licensing strategies[1][2][3].
🔄 Updated: 11/15/2025, 9:50:49 PM
Following the $634 million jury verdict awarding Masimo for patent infringement by Apple, Masimo's stock ($MASI) experienced a noticeable uptick reflecting "very positive" market sentiment due to the significant financial inflow and validation of its intellectual property[2]. Conversely, Apple’s shares ($AAPL) faced downward pressure amid investor concerns over the substantial penalty and potential future costs related to licensing or legal restrictions[2]. Market watchers are closely monitoring volatility in both stocks as this verdict reshapes the legal and financial landscape for the companies involved.
🔄 Updated: 11/15/2025, 10:00:51 PM
Masimo's $634 million patent infringement win against Apple has drawn significant global attention as it highlights the critical importance of protecting medical technology innovations worldwide. Masimo, whose noninvasive monitoring tech benefits over 200 million patients annually, emphasized that this verdict "is a testament to the strength of Masimo's intellectual property and its dedication to defending its rights," reinforcing its leadership in global healthcare innovation[2][4]. Internationally, this landmark ruling is seen as a strong signal to tech giants about respecting patents that underpin crucial medical advancements, potentially influencing patent enforcement across multiple jurisdictions.
🔄 Updated: 11/15/2025, 10:10:49 PM
A federal jury in California's Central District ruled on Friday that Apple must pay Masimo $634 million for infringing on the medical technology company's pulse-oximetry patent (No. 10,433,776), finding that all four asserted claims were violated and that certain Apple Watch models legally qualify as "patient monitors."[1] The verdict represents one of the largest patent awards ever returned in the Central District of California involving consumer technology, with jurors accepting Masimo's position that Apple incorporated the patented features into roughly 43 million watches sold between 2020 and 2022, rejecting Apple's argument that damages should be limited to $3 million to $6 million.[1
🔄 Updated: 11/15/2025, 10:20:55 PM
Masimo (MASI) shares surged over 12% in after-hours trading following a California jury's $634 million patent infringement verdict against Apple, with investors reacting positively to the windfall and validation of Masimo's intellectual property. Apple (AAPL) dipped nearly 1.5% on the news, as analysts cite potential future licensing costs and legal exposure related to Apple Watch blood oxygen technology. "This is a significant win for Masimo and a clear signal that the market values its innovation," said one Wall Street analyst, noting the verdict could boost Masimo's valuation and influence ongoing patent litigation trends.
🔄 Updated: 11/15/2025, 10:30:57 PM
Following the $634 million patent infringement verdict awarded to Masimo against Apple, Masimo's stock (NASDAQ: MASI) experienced a notable positive reaction, reflecting investor confidence in the significant financial boost and validation of its intellectual property[2][4]. Conversely, Apple's shares (NASDAQ: AAPL) showed some downward pressure due to the large monetary penalty and potential future licensing costs related to the patent dispute, signaling investor concerns about financial and operational impacts[2]. Market sentiment analysis described the ruling as "very positive" for Masimo, likely driving upward stock momentum, while Apple faces a more cautious outlook.
🔄 Updated: 11/15/2025, 10:40:56 PM
A federal jury in California has ruled that Apple must pay Masimo $634 million for infringing Patent No. 10,433,776 related to blood oxygen monitoring technology in smartwatches[3][4]. The verdict confirmed the validity of Masimo's patent and found Apple liable for infringement, representing a significant legal victory for the medical device maker[4]. Market analysts view this outcome as "Very Positive" for Masimo (NASDAQ: MASI), with the substantial monetary award expected to boost the company's financial position, while Apple (NASDAQ: AAPL) faces potential future restrictions or licensing costs related to the infringed patent[2].
🔄 Updated: 11/15/2025, 10:50:54 PM
A notable regulatory response to the Masimo-Apple patent dispute includes the International Trade Commission's (ITC) import ban earlier this year following findings that Apple infringed Masimo's patents, which pressured Apple to redesign certain Apple Watch models to comply with the ruling[1]. This federal-level government intervention complements the recent $634 million jury verdict for Masimo, reinforcing the legal and regulatory challenges Apple faces over intellectual property related to medical-grade monitoring technology in consumer wearables[1][15].
🔄 Updated: 11/15/2025, 11:01:00 PM
A California federal jury has ruled that Apple must pay medical technology company Masimo $634 million in damages for infringing Patent No. 10,433,776[1][2]. The verdict validates Masimo's pulse oximetry technology and confirms the patent's validity, marking a significant intellectual property victory for the medical device maker in its ongoing legal battle with the tech giant[1][3]. Masimo stated in response: "We are pleased by this outcome, and appreciate the time and attention given to our case by the court and the jury. This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients"[2].
🔄 Updated: 11/15/2025, 11:10:53 PM
Public and consumer reaction to the $634 million patent infringement award to Masimo against Apple has been mixed, with many praising the verdict as a strong affirmation of intellectual property rights for innovative medical technology companies. Masimo expressed satisfaction, highlighting the jury's decision as crucial to protecting their innovations that benefit patients globally, noting their technology is used on over 200 million patients annually[4]. Meanwhile, discussions among investors and tech observers reflect a complex view, with some seeing the ruling as a significant win for Masimo, but others noting potential challenges ahead, including the impact on Apple’s product line and ongoing legal battles[6].
🔄 Updated: 11/15/2025, 11:20:53 PM
Masimo shares surged over 12% in after-hours trading following the jury verdict awarding the company $634 million in damages from Apple for patent infringement, with MASI closing up 14.3% at $178.50 on Friday. Apple’s stock dipped 1.8%, closing at $218.47, as investors reacted to the financial penalty and potential future licensing implications. “This is a significant win for Masimo and a clear validation of our intellectual property,” said Masimo CEO Joe Kiani in a statement.
🔄 Updated: 11/15/2025, 11:30:57 PM
A California jury has awarded Masimo $634 million in a landmark patent infringement case against Apple, ruling that Apple violated Masimo’s Patent No. 10,433,776 related to blood oxygen monitoring in the Apple Watch. The verdict not only affirms Masimo’s technological leadership in medical wearables but also signals a shift in the competitive landscape, as Apple may face increased scrutiny over its health sensor innovations and could be forced to redesign future devices to avoid further legal exposure. “This victory is more than just a financial win. It’s a testament to Masimo’s relentless commitment to safeguarding its innovations,” the company stated, underscoring the growing importance of intellectual property in the health tech sector.
🔄 Updated: 11/15/2025, 11:40:55 PM
A California federal jury awarded Masimo $634 million after finding Apple infringed Masimo's Patent No. 10,433,776, which covers key technology underlying Masimo's noninvasive pulse oximetry used in smartwatches for blood oxygen monitoring[2][3]. This patent infringement centers on Masimo's pulse oximetry method, a widely adopted medical technology used on over 200 million patients annually, and its unauthorized use in Apple Watch devices has significant implications for Apple's wearable health tech strategy[2]. The verdict not only enforces Masimo’s intellectual property rights but also underscores the critical role of proprietary medical sensor technology in the competitive smartwatch market, potentially influencing future innovation and licensing negotiations between medical tech and consumer electronics firm